Skip to content

Efficacy of Smoking Cessation Intervention for Head and Neck Cancer Patients

Smoking Cessation Intervention for Head and Neck Cancer Patients: A Prospective Randomised Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03786172
Enrollment
100
Registered
2018-12-24
Start date
2015-01-31
Completion date
2019-12-31
Last updated
2018-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Neoplasms, Smoking

Keywords

Smoking cessation, Intervention, Head and Neck neoplasms, Cognitive therapy

Brief summary

The purpose of this study is to determine whether a brief smoking ENT-resident-based intervention increased smoking cessation in patients with Head and Neck cancer attending a Lebanese university hospital, as compared with usual care.

Detailed description

The primary objective of the study is to evaluate the effectiveness of a brief smoking physician-based intervention on smoking-cessation rates in Head and Neck cancer adult patients. The secondary objective is to assess predictors of long-term smoking cessation in such patients. After an initial assessment of demographic, clinical and smoking characteristics, the patients are randomised (based on a computer randomisation program) in 2 groups: * Group 1 will receive the usual care in Lebanon, which consists of a brief advice to quit (10 seconds) * Group 2 will receive a brief (10-15 minutes) standardised smoking cessation counseling session peri-operatively (immediately before or after surgery), by an ENT residents, based on the 5 A's motivational interviewing model: * Ask (screen for tobacco use) * Advise (provide a personalised and strong quit message) * Assess (evaluate the smoker's willingness and readiness to quit) * Assist (provide cessation counseling, pharmacotherapy, self-help guides) * Arrange (for followup to prevent relapse, and evaluate cessation progress) A motivational gadget will be distributed to group 2 patients. They will also be offered nicotine replacement therapy (nicotine transdermal patches) for a total of 8 weeks. This will be followed by a telephone boost session after 6 weeks. The follow-up at 3, 6 and 12 months will be done, for the 2 groups, by a person not implicated in either the randomisation or the intervention (single-blind), in person or, if impossible, by telephone.

Interventions

BEHAVIORALSmoking cessation Intervention

* A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange) * A motivational gadget distributed to the patients * Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients

BEHAVIORALUsual care

A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident

Sponsors

Hotel Dieu de France Hospital
CollaboratorOTHER
Saint-Joseph University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Head and Neck cancer * Patients hospitalised from biopsy or surgery * Current smokers = smokers in the past 3 months * Reachable by phone

Exclusion criteria

* Nonsmokers in the past 3 months * Current drug dependance * Pregnant women * Psychiatric conditions * Patients under current smoking cessation intervention

Design outcomes

Primary

MeasureTime frameDescription
7-day point prevalence abstinence12 monthsThe patient is considered abstinent if he reported not smoking for at least 7 days before the interview

Secondary

MeasureTime frameDescription
continuous abstinence12 monthscontinuous abstinence from smoking at the time of follow-up, since the quit date

Countries

Lebanon

Contacts

Primary ContactDiane Helou, ENT resident
diane_helou@hotmail.com96171112426
Backup ContactNayla Matar, MD ENT
naylamatar@gmail.com9613277725

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026